Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abeona Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -45.21%. Abeona Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.75.
Abeona Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -25.83%.
Abeona Therapeutics ROE % Adjusted to Book Value Related Terms
Abeona Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Abeona Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abeona Therapeutics ROE % Adjusted to Book Value Chart
STU:PCJ vs RCKT, UPB, PALI: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Abeona Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abeona Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Abeona Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -25.83% mean?
Abeona Therapeutics (STU:PCJ) has a ROE % Adjusted to Book Value of -25.83% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Abeona Therapeutics and its competitors.
Is Abeona Therapeutics' ROE % Adjusted to Book Value too high?
Abeona Therapeutics' current ROE % Adjusted to Book Value is -25.83%. Overall, Abeona Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abeona Therapeutics' ROE % Adjusted to Book Value compare to RCKT and UPB?
Abeona Therapeutics' ROE % Adjusted to Book Value of -25.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Abeona Therapeutics and its competitors. Abeona Therapeutics's current ROE % Adjusted to Book Value is -25.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abeona Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Abeona Therapeutics (STU:PCJ) is currently considered Possible Value Trap. The stock's GF Value™ is €15.12, compared to a current price of €6.23 — trading 58.8% below its estimated fair value. The current ROE % Adjusted to Book Value is -25.83%. Abeona Therapeutics' overall GF Score™ is 51/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Abeona Therapeutics (STU:PCJ), the current ROE % Adjusted to Book Value is -25.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?
Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued.
The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12.
GuruFocus considers Abeona Therapeutics to be Possible Value Trap.
Key valuation signals for STU:PCJ:
ROE % Adjusted to Book Value: -25.83%
GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score
Get the complete analysis for STU:PCJ
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:PCJ has been successfully added to your 
